GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Gallbladder and Pancreas/Genetic Variants Linked to Pancreatic IPMN Development
58

Genetic Variants Linked to Pancreatic IPMN Development

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated September 1, 2025

The study identified genetic variants that are significantly linked to the development of pancreatic intraductal papillary mucinous neoplasms (IPMNs), which are cystic lesions in the pancreas that have the potential to progress into pancreatic adenocarcinoma.

Key Findings:

  1. Genome-Wide Association Analysis:
  • Researchers analyzed genetic data from 68,931 individuals in the Mass General Brigham Biobank, including 2,525 individuals diagnosed with IPMNs.
  • The analysis focused on common single nucleotide variants (SNVs) with a frequency of at least 5%.
  1. Significant Genetic Locus:
  • The study identified a significant genetic association on chromosome 19.
  • Two specific variants, rs681343 and rs601338, were strongly linked to an increased risk of developing IPMNs.
  1. Validation:
  • These findings were validated in an independent cohort of 5,014 individuals, further confirming the association between these variants and IPMN risk.

Role of FUT2 Gene:

The variant rs601338 occurs in a noncoding exon of the fucosyltransferase 2 (FUT2) gene. This variant introduces a stop codon, which halts the synthesis of the FUT2 protein. The FUT2 gene is critical for several biological functions:

  • Enzyme Function: FUT2 encodes an enzyme involved in the Lewis antigen system, which plays a role in determining blood group antigens and secretor status.
  • Mucin Production: The enzyme contributes to mucin synthesis, which is important for maintaining ductal homeostasis in the pancreas.
  • Regulation of Tumor Markers: FUT2 influences levels of tumor markers such as carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA 19-9), which are often elevated in pancreatic diseases.

Biological Implications:

The study suggests that genetic variations in FUT2 contribute to the development of IPMNs by disrupting mucin synthesis and ductal homeostasis. This disruption may create a favorable environment for the formation of cystic lesions and potentially their malignant transformation.

Conclusion:

The identification of FUT2 variants, particularly rs601338, provides a biologically plausible link between genetic variation, mucin production, and the pathogenesis of pancreatic neoplasms. These findings offer insights into the genetic underpinnings of IPMNs and may aid in the development of targeted screening strategies or therapeutic interventions for individuals at risk of pancreatic cancer.

Related Q&A

59

Pleural effusion, acute pancreatitis and Mortality

Pleural effusion (PE) is a significant clinical finding in patients with acute pancreatitis (AP) and has been shown to be strongly associated with increased severity and mortality in...

60

TGF-Beta and Chronic Pancreatitis

TGF-β and Chronic Pancreatitis Transforming Growth Factor-Beta (TGF-β) is a multifunctional cytokine that plays a key role in chronic pancreatitis (CP), particularly in driving fibrosis and disease progression....

61

Fatty Pancreas and PANDORA Hypothesis

The PANDORA Hypothesis (Pancreatic Diseases Originating from Intrapancreatic Fat) is a groundbreaking concept that identifies fat accumulation within the pancreas—referred to as fatty pancreas disease (FPD)—as a common...

62

Native Hawaiian pancreatic cancer disparity study

The study on pancreatic cancer disparities among Native Hawaiians, conducted as part of the Multiethnic Cohort Study, revealed significant findings about the heightened risk faced by this population...

01

Nivolumab–Ipilimumab Shows Promising Activity in Gallbladder Cancer: Clinical Cancer Research | August 2026

Introduction: Dual immune checkpoint blockade with nivolumab plus ipilimumab has shown activity across several malignancies, but its role in advanced biliary tract cancer remains uncertain. The Phase II...

02

Targeting Cholesterol Metabolism is A New Strategy to Overcome Chemotherapy Resistance in Pancreatic Cancer: National Cancer Institute Research | August 2026

Introduction: Pancreatic ductal adenocarcinoma (PDAC) frequently develops resistance to chemotherapy through metabolic adaptations that enhance tumor survival. New research from the University of Oklahoma is investigating whether pancreatic...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer